Business
PDMR Notification RSU Vesting
PureTech Health plc announced that a person discharging managerial responsibilities, Eric Elenko, received 112,509 ordinary shares on March 12, 2026, following the vesting of restricted share units granted on May 22, 2023. The shares were issued at a price of 0.01 GBP each, based on an average closing price of 123.67 pence per share over the three trading days prior to the vesting date of March 11, 2026. After this issuance, the company's total issued ordinary share capital stands at 257,927,489 shares. Disclaimer*
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n13 March 2026\nPureTech Health plc\n \nPDMR Notifications\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that the award of restricted share units (\"RSUs\") granted by PureTech on 22 May 2023 to a certain person discharging managerial responsibilities (\"PDMR\") pursuant to its Performance Share Plan (\"PSP\") vested on 11 March 2026 following satisfaction of certain performance conditions measured over the three year period to 31 December 2025.\nThe PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 12 March 2026. The market price per ordinary share in the Company used to calculate the amount payable to the PDMR and the amount of shares to be issued to the PDMR was 123.67 pence, being the average closing price of the Company's shares over the three-trading day period immediately preceding the vesting date, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.34.\nThe Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMR, 14,859,738 shares of which are held in treasury by the Company.\nPDMR Notification\n \nThe information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.\n\n\n\n\n1\n\n\nDetails of the person discharging managerial responsibilities/person closely associated\n\n\n\n\na)\n\n\nName\n\n\nEric Elenko\n\n\n\n\n2\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nPresident\n\n\n\n\nb)\n\n\nInitial notification/Amendment\n\n\nInitial Notification\n\n\n\n\n3\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na)\n\n\nName\n\n\nPureTech Health plc\n\n\n\n\nb)\n\n\nLEI\n\n\n213800LVPDNO2Z9T9I39\n\n\n\n\n4\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDescription of the financial instrument, type of instrument\n\n\n\n\n\n\nOrdinary Shares of PureTech Health plc\nISIN GB00BY2Z0H74\n\n\n\n\n\n\n\n...